Literature DB >> 18841292

Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia.

Nicole L Whitlatch1, Stephanie L Perry, Thomas L Ortel.   

Abstract

Laboratory testing for heparin-induced thrombocytopenia (HIT) includes the highly sensitive, though less specific, heparin/platelet factor 4 (PF4) ELISA. A confirmatory test with excess heparin is routinely performed on positive ELISA results to improve test specificity; the significance of a negative confirmatory result is unknown. The aim was firstly to evaluate the clinical utility of the PF4 ELISA confirmatory assay, secondly to examine the relationship between ELISA optical density (OD) value and clinical diagnosis of HIT, and thirdly to assess current practice at a tertiary care medical centre regarding patients with anti-heparin/PF4 antibodies. Patients with anti-heparin/PF4 antibodies detected by commercial ELISA during 2005 were identified. A confirmatory test was performed on positive ELISA results. Patients were labeled confirmatory positive (confirm+) or confirmatory negative (confirm-). Patients were classified as HIT+ (met criteria for HIT), HIT? (HIT possible), and HIT- (did not meet criteria for HIT) utilizing ACCP guidelines. One hundred fifteen patients with anti-heparin/PF4 antibodies were identified. Ninety-eight patients were confirm+; 17 were confirm-. The majority of confirm+ patients were HIT+ or HIT?(72%); the majority of confirm- patients were HIT-(81%). Patients who were HIT+/confirm+ had higher ELISA OD values than patients who were HIT?/confirm+ or HIT-/confirm+ (p = 0.031, p = 0.001). Two confirm- patients were HIT+, one was HIT?; all had high ELISA OD values. Although confirm+ status correlated with clinical HIT, the confirmatory procedure misclassified some patients by yielding a confirm- result despite clinical HIT with high ELISA OD values. Future studies should compare higher ELISA OD values with the confirmatory procedure as strategies to improve ELISA diagnostic specificity for HIT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18841292      PMCID: PMC2575642          DOI: 10.1160/th08-02-0118

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  17 in total

1.  Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.

Authors:  G K Lo; D Juhl; T E Warkentin; C S Sigouin; P Eichler; A Greinacher
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

2.  No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure.

Authors:  T E Warkentin; J I Sheppard
Journal:  J Thromb Haemost       Date:  2006-01       Impact factor: 5.824

Review 3.  Clinical practice. Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

4.  Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.

Authors:  J I Zwicker; L Uhl; W-Y Huang; B H Shaz; K A Bauer
Journal:  J Thromb Haemost       Date:  2004-12       Impact factor: 5.824

5.  Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy.

Authors:  U Pedersen-Bjergaard; M Andersen; P B Hansen
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

6.  Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3.

Authors:  N Lubenow; P Eichler; T Lietz; A Greinacher
Journal:  J Thromb Haemost       Date:  2005-11       Impact factor: 5.824

7.  Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?

Authors:  Theodore E Warkentin; Jo-Ann I Sheppard; Jane C Moore; Kathleen M Moore; Christopher S Sigouin; John G Kelton
Journal:  J Lab Clin Med       Date:  2005-12

8.  A 14-year study of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Am J Med       Date:  1996-11       Impact factor: 4.965

9.  Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies.

Authors:  Claire Pouplard; Marc Antoine May; Sandra Regina; Michel Marchand; Jacques Fusciardi; Yves Gruel
Journal:  Br J Haematol       Date:  2005-03       Impact factor: 6.998

10.  Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia.

Authors:  F Fabris; G Luzzatto; B Soini; R Ramon; R Scandellari; M L Randi; A Girolami
Journal:  J Intern Med       Date:  2002-08       Impact factor: 8.989

View more
  15 in total

1.  The Clinical Utility of the Heparin Neutralization Assay in the Diagnosis of Heparin-Induced Thrombocytopenia.

Authors:  Gang Zheng; Michael B Streiff; Clifford M Takemoto; Jennifer Bynum; Elise Gelwan; Jayesh Jani; Danielle Judge; Thomas S Kickler
Journal:  Clin Appl Thromb Hemost       Date:  2017-08-04       Impact factor: 2.389

2.  Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia.

Authors:  Nicole L Whitlatch; David F Kong; Ara D Metjian; Gowthami M Arepally; Thomas L Ortel
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

3.  Platelet factor 4/heparin-particle gel immunoassay (PaGIA) is a weak method for heparin-induced thrombocytopenia (HIT) evaluation of post cardio-pulmonary bypass surgery patients.

Authors:  Chezi Ganzel; Jacob Rowe; David Raveh
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

4.  Plasmapheresis may be an option in urgent management of heparin-induced thrombocytopenia in the setting of acute intracerebral hemorrhage.

Authors:  Emitseilu Iluonakhamhe; Oluchukwu Ibekwe; Sophie Samuel; Asma Zakaria
Journal:  Neurocrit Care       Date:  2015-02       Impact factor: 3.210

5.  Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients.

Authors:  Chieh Kuo; Chiang-Chin Tsai; Chien-An Chen; Yueh-Feng Tsai; Yen-Hsun Chen
Journal:  Acta Cardiol Sin       Date:  2017-03       Impact factor: 2.672

6.  Anti-PF4/heparin antibodies are associated with arteriovenous fistula thrombosis in non-diabetic hemodialysis patients.

Authors:  Yueh-Feng Tsai; Chien-An Chen; Chieh Kuo; Kao-Chang Lin
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

7.  Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia.

Authors:  Matthew T Rondina; Amanda Walker; Robert C Pendleton
Journal:  Hosp Pract (1995)       Date:  2010-04

Review 8.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

9.  Heparin-induced thrombocytopenia: ELISA optical density value and 4T score in correlation with panel donor platelets activation in functional flow cytometric assay.

Authors:  Klara Železnik; Primož Rožman; Eva Kocjan; Elvira Maličev
Journal:  Blood Transfus       Date:  2020-10-09       Impact factor: 3.443

10.  Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.

Authors:  Tamam Bakchoul; Andreas Greinacher
Journal:  Ther Adv Hematol       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.